Cancer Vaccines Market
PUBLISHED: 2023 ID: SMRC23065
SHARE
SHARE

Cancer Vaccines Market

Cancer Vaccines Market Forecasts to 2028 - Global Analysis By Product Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines and Antigen/Adjuvant Cancer Vaccines), Application, End users and By Geography

4.7 (27 reviews)
4.7 (27 reviews)
Published: 2023 ID: SMRC23065

This report covers the impact of COVID-19 on this global market
Loading...

Years Covered

2020-2028

Estimated Year Value (2022)

US $7.50 BN

Projected Year Value (2028)

US $18.95 BN

CAGR (2022 - 2028)

16.7%

Regions Covered

North America, Europe, Asia Pacific, South America, and Middle East & Africa

Countries Covered

US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa

Largest Market

North America

Highest Growing Market

Europe


According to Stratistics MRC, the Global Cancer Vaccines Market is accounted for $7.50 billion in 2022 and is expected to reach $18.95 billion by 2028 growing at a CAGR of 16.7% during the forecast period. Cancer vaccines are drugs that are thought of as biological response modifiers. These biological response modifiers work by boosting the body's immune system's capacity to combat cancer. There are two different kinds of cancer vaccines: therapeutic and preventative. In order to prevent cancer in healthy individuals, preventive cancer vaccines are used. In order to boost their immune systems ability to combat the disease, cancer patients receive therapeutic cancer vaccines. Children and adults alike can receive cancer vaccines intravenously .

According to statistics published by the World Cancer Research Fund (WCRF), there were about 18.1 million cancer cases worldwide in 2020, of which 9.3 million were males and 8.8 million females.

Market Dynamics:

Driver:

Growing strategic partnerships among major market players


The market is characterized by a significant focus on the introduction of novel vaccines by industry players like Merck & Co., Inc., GSK plc, and others. However, a sizable market gap is feared due to a lack of product approvals and an imbalance of therapeutic indications in the pipeline for new vaccines. Additionally, small and mid-size biotech businesses as well as academic institutions working to develop novel cancer vaccines are having trouble finding funding and investments. Therefore, new business models that encourage collaboration are being adopted so that these players can access international markets and provide the market with cutting-edge new products. As a result, a number of mid-sized immunotherapy players involved in the research and development of prophylactic and therapeutic vaccines are now working with well-known companies in the industry to carry out clinical trials to gauge the safety and effectiveness of vaccines.

Restraint:

Limiting the use of cancer vaccines with personalized medicine advances


Cancer, one of the leading causes of death worldwide, is a complex and heterogeneous disease. Therapeutic cancer vaccines target the cancer cells rather than the disease's underlying cause, whereas preventive cancer vaccines work to bolster the body's natural defenses against the disease. Additionally, these vaccines are a form of immunotherapy that only has a small number of cancer types for which they have received global product approval. Based on their molecular subtypes, some cancer types (colon, breast, and non-Hodgkin's lymphoma) have even more detailed classifications. Additionally, the location or stage of the cancer affects how certain markers are expressed within the same tumor. In order to improve the prognosis for these cancer types, more precise treatment methods are required in addition to cancer vaccines. A new approach to prevention and treatment in oncology is personalized or precision medicine. It may alter treatment in ways that target the tumor's oncogenic drivers and influence its environment.

Opportunity:

The expansion of cancer vaccine clinical trials


PDAC, or pancreatic ductal adenocarcinoma, is a common form of pancreatic cancer for which there are no curative therapies. Data from the first phase of a clinical trial for BioNTech's PDAC vaccine against PDAC was made public. The mRNA vaccination developed by BioNTech is used to deliver the genetic code for the neoantigen to the patient's cells. The code instructs the cells to produce the neoantigens, proteins created by cancer cells. These proteins are produced to help the immune system attack the tumor directly.

Threat:

Lengthy regulatory approvals and high developing cost


Market growth is anticipated to be constrained during the forecast period due to the high cost of developing cancer vaccines and the prolonged time required for vaccine manufacturing. Additionally, a sizable market gap is threatened by a lack of product approvals and an imbalance of therapeutic indications in the pipeline of upcoming vaccines.

Covid-19 Impact:

On January 30, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of global concern. A total of 210 countries around the world have been impacted by COVID-19. Due to closures in several COVID-19-affected countries and an increase in the number of sick healthcare workers following the COVID-19 pandemic, which resulted in a shortage, companies that manufacture and distribute cancer vaccines have only been minimally impacted by COVID-19.

The creavax segment is expected to be the largest during the forecast period

CreaVax is expected to expand significantly during the forecast period. The patient's peripheral blood mononuclear cells (PBMC) are used to make the autologous dendritic cell-based cancer vaccine, which is sensitized with tumor lysate and KLH before maturing into dendritic cells (Keyhole Limpet Hemocyanin). Creagene released Creavax, a therapeutic vaccine for renal cell carcinoma. The effectiveness of CreaVax in the treatment of hepatocellular carcinoma is currently being studied in a Phase III clinical trial.

The adult vaccines segment is expected to have the highest CAGR during the forecast period

The adult vaccine market segment had the largest market share. Additionally, a large number of researchers around the world are conducting in-depth research to develop efficient vaccine candidates to realize potential therapeutic strategies. For instance, Northwest Biotherapeutics of Maryland will announce in March 2022 the start of production of the first personalized dendritic cell-based cancer vaccine at its new production facility in Sawston, UK, using advanced therapy medicinal products for the treatment of a glioblastoma case on compassionate grounds.

Region with highest share:

The largest revenue share came from North America. The factors driving the market during the forecast period include the rising incidence of cancer, rising research expenditures, an increase in clinical trials by industry participants, and regulatory approvals for cancer vaccines. For instance, the American Cancer Society predicts that in 2021 there will be 608,570 cancer deaths in the United States and an estimated 1.9 million new cancer cases. In contrast, the number of Americans who will receive a cancer diagnosis in 2022 will be close to 1.9 million. Breast cancer will be the most common cancer diagnosis in 2018, affecting an estimated 287,850 women and 2,710 men. The most frequent cancer diagnosis in men and the second most frequent overall is prostate cancer.

Region with highest CAGR:

Europe's market is expected to grow significantly. This can be attributed to factors such as the rising demand for cancer vaccines, the rising incidence of cancer, the increase in support for research studies from cancer societies across Europe, and emerging market players in the area, all of which have a positive impact on the market for dendritic cell cancer vaccines.



Key players in the market


Some of the key players in Cancer Vaccines market include Aduro Biotech Inc., Advaxis Inc., Amgen Inc., Argos Therapeutics, Astellas Pharma Inc., Astrazeneca Plc., Batavia Bioservices, Bristol-Myers Squibb Company, Csl Limited, Dandrit Biotech, Dynavax Technologies Corporation, Generex Biotechnology Corporation, Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Sanpower Corporation, Sanpower Group Co. Ltd. And Vaccinogen, Inc.

Key Developments:

In June 2022, Treos Bio Limited, a biotechnology company, announced the first patient dosed in a phase 2 trial of polypepi1018 in combination with pd-l1-inhibitor manufactured by F. Hoffmann-La Roche AG for the treatment of metastatic colorectal cancer.

In October 2020, Vaccibody AS, a clinical-stage biopharmaceutical company, announced its worldwide license and collaboration agreement with Genentech, Inc., a member of the Roche Group, for the development and commercialization of DNA-based individualized neoantigen vaccines (DNA cancer vaccines) for the treatment of cancers.

In June 2020, UbiVac, Inc. announced a clinical trial collaboration with Bristol Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of UbiVac's investigational product, DPV-001, in combination with Immunotherapy for Advanced Triple Negative Breast Cancer.

Product Types Covered:
• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines

Technologies Covered:
• Dendritic Cells (DC) Cancer Vaccines
• Recombinant Cancer Vaccines
• Whole-cell Cancer Vaccines
• Antigen/Adjuvant Cancer Vaccines
• Viral Vector & DNA Cancer Vaccines
• Subunit Vaccines
• Conjugate Vaccines
• Inactivated Vaccines
• Live Attenuated Vaccines
• Other Technologies

Applications Covered:
• Prostate Cancer
• Cervical Cancer
• Other Applications

End Users Covered:
• Pediatrics
• Adults
• Other End users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 Application Analysis
3.9 End User Analysis
3.10 Emerging Markets
3.11 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Cancer Vaccines Market, By Product Type
5.1 Introduction
5.2 Preventive Cancer Vaccines
5.3 Therapeutic Cancer Vaccines

6 Global Cancer Vaccines Market, By Technology
6.1 Introduction
6.2 Dendritic Cells (DC) Cancer Vaccines
6.3 Recombinant Cancer Vaccines
6.4 Whole-cell Cancer Vaccines
6.5 Antigen/Adjuvant Cancer Vaccines
6.6 Viral Vector & DNA Cancer Vaccines
6.7 Subunit Vaccines
6.8 Conjugate Vaccines
6.9 Inactivated Vaccines
6.10 Live Attenuated Vaccines
6.11 Other Technologies

7 Global Cancer Vaccines Market, By Application
7.1 Introduction
7.2 Prostate Cancer
7.3 Cervical Cancer
7.4 Other Applications

8 Global Cancer Vaccines Market, By End User
8.1 Introduction
8.2 Pediatrics
8.3 Adults
8.4 Other End Users

9 Global Cancer Vaccines Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa

10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling
11.1 Aduro Biotech Inc.
11.2 Advaxis Inc.
11.3 Amgen Inc.
11.4 Argos Therapeutics
11.5 Astellas Pharma Inc.
11.6 Astrazeneca Plc.
11.7 Batavia Bioservices,
11.8 Bristol-Myers Squibb Company
11.9 Csl Limited
11.10 Dandrit Biotech
11.11 Dynavax Technologies Corporation
11.12 Generex Biotechnology Corporation
11.13 Immunocellular Therapeutics, Ltd
11.14 Merck & Co., Inc.
11.15 Sanpower Corporation
11.16 Sanpower Group Co. Ltd.
11.17 Vaccinogen, Inc.

List of Tables
1 Global Cancer Vaccines Market Outlook, By Region (2020-2028) ($MN)
2 Global Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
3 Global Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
4 Global Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
5 Global Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
6 Global Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
7 Global Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
8 Global Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
9 Global Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
10 Global Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
11 Global Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
12 Global Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
13 Global Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
14 Global Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
15 Global Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
16 Global Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
17 Global Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
18 Global Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
19 Global Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
20 Global Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
21 Global Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
22 Global Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
23 Global Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
24 North America Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
25 North America Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
26 North America Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
27 North America Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
28 North America Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
29 North America Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
30 North America Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
31 North America Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
32 North America Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
33 North America Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
34 North America Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
35 North America Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
36 North America Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
37 North America Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
38 North America Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
39 North America Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
40 North America Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
41 North America Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
42 North America Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
43 North America Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
44 North America Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
45 North America Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
46 North America Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
47 Europe Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
48 Europe Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
49 Europe Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
50 Europe Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
51 Europe Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
52 Europe Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
53 Europe Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
54 Europe Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
55 Europe Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
56 Europe Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
57 Europe Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
58 Europe Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
59 Europe Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
60 Europe Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
61 Europe Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
62 Europe Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
63 Europe Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
64 Europe Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
65 Europe Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
66 Europe Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
67 Europe Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
68 Europe Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
69 Europe Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
70 Asia Pacific Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
71 Asia Pacific Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
72 Asia Pacific Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
73 Asia Pacific Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
74 Asia Pacific Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
75 Asia Pacific Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
76 Asia Pacific Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
77 Asia Pacific Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
78 Asia Pacific Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
79 Asia Pacific Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
80 Asia Pacific Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
81 Asia Pacific Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
82 Asia Pacific Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
83 Asia Pacific Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
84 Asia Pacific Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
85 Asia Pacific Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
86 Asia Pacific Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
87 Asia Pacific Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
88 Asia Pacific Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
89 Asia Pacific Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
90 Asia Pacific Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
91 Asia Pacific Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
92 Asia Pacific Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
93 South America Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
94 South America Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
95 South America Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
96 South America Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
97 South America Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
98 South America Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
99 South America Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
100 South America Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
101 South America Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
102 South America Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
103 South America Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
104 South America Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
105 South America Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
106 South America Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
107 South America Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
108 South America Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
109 South America Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
110 South America Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
111 South America Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
112 South America Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
113 South America Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
114 South America Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
115 South America Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
116 Middle East & Africa Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
117 Middle East & Africa Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
118 Middle East & Africa Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
119 Middle East & Africa Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
120 Middle East & Africa Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
121 Middle East & Africa Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
122 Middle East & Africa Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
123 Middle East & Africa Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
124 Middle East & Africa Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
125 Middle East & Africa Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
126 Middle East & Africa Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
127 Middle East & Africa Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
128 Middle East & Africa Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
129 Middle East & Africa Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
130 Middle East & Africa Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
131 Middle East & Africa Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
132 Middle East & Africa Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
133 Middle East & Africa Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
134 Middle East & Africa Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
135 Middle East & Africa Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
136 Middle East & Africa Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
137 Middle East & Africa Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
138 Middle East & Africa Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)

List of Figures

RESEARCH METHODOLOGY


Research Methodology

We at Stratistics opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.

Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.

Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.

Data Mining

The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.

Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.

Data Analysis

From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:

  • Product Lifecycle Analysis
  • Competitor analysis
  • Risk analysis
  • Porters Analysis
  • PESTEL Analysis
  • SWOT Analysis

The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.


Data Validation

The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.

We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.


For more details about research methodology, kindly write to us at info@strategymrc.com

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials